title: Tenidap in patients with rheumatoid arthritis. A 4-week, placebo-controlled study.
abstract: The present double-blind, placebo-controlled study was conducted to compare the safety and efficacy of tenidap in patients with rheumatoid arthritis (RA). Patients with flare of active RA following NSAID withdrawal were randomized to receive either placebo (n = 67) or tenidap (n = 131; 40-200 mg/day). The mean changes from baseline in efficacy and biochemical variables were compared between treatment groups at endpoint (4 weeks). The improvements in four of the five primary efficacy variables were significantly greater in the tenidap group compared with the placebo group (p < 0.01). Tenidap was also associated with an 18% reduction in erythrocyte sedimentation rate (ESR) and a marked, 51%, reduction in serum C-reactive protein (CRP) level, both of which were significantly greater than the changes in the placebo group (p < 0.05). The percentage of patients who discontinued because of side effects was the same in both groups (3%). In conclusion, tenidap 40-200 mg/day was effective and well tolerated in the treatment of patients with RA for 4 weeks.
authors.affiliation: University of Nevada, Reno School of Medicine 89503, USA.
authors.forename: H M
authors.initials: HM
authors.lastname: Prupas
authors.forename: L D
authors.initials: LD
authors.lastname: Loose
authors.forename: J S
authors.initials: JS
authors.lastname: Spindler
authors.forename: A J
authors.initials: AJ
authors.lastname: Dietz
authors.forename: O B
authors.initials: OB
authors.lastname: Gum
authors.forename: M H
authors.initials: MH
authors.lastname: Weisman
authors.forename: G
authors.initials: G
authors.lastname: Gordon
authors.forename: R E
authors.initials: RE
authors.lastname: Wolf
authors.forename: R A
authors.initials: RA
authors.lastname: Turner
authors.forename: R L
authors.initials: RL
authors.lastname: Collins
authors.forename: B F
authors.initials: BF
authors.lastname: Germain
authors.forename: P
authors.initials: P
authors.lastname: Katz
authors.forename: S P
authors.initials: SP
authors.lastname: Ballou
authors.forename: F
authors.initials: F
authors.lastname: Wolfe
authors.forename: J C
authors.initials: JC
authors.lastname: Daniels
authors.forename: P A
authors.initials: PA
authors.lastname: April
authors.forename: R F
authors.initials: RF
authors.lastname: Willkens
authors.forename: K
authors.initials: K
authors.lastname: Pariser
authors.forename: B
authors.initials: B
authors.lastname: Hepburn
authors.forename: T M
authors.initials: TM
authors.lastname: Zizic
authors.forename: N
authors.initials: N
authors.lastname: Ting
authors.forename: M
authors.initials: M
authors.lastname: Mehrban
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004064:Digestive System / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000078183:Oxindoles; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007211:Indoles; D000078183:Oxindoles; C062866:tenidap